Integrated analysis of thyroid cancer public datasets reveals role of post-transcriptional regulation on tumor progression by targeting of immune system mediators

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Geraldo, Murilo V ^a,b   Kimura, Edna T ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; TUMOR MARKER;

ANAPLASTIC THYROID CANCER; ARTICLE; CANCER GENOME ATLAS DATABASE; DIFFERENTIATED THYROID CANCER; GENE EXPRESSION; GENETIC DATABASE; HUMAN; IMMUNE SYSTEM; OVERALL SURVIVAL; POSTTRANSCRIPTIONAL REGULATION; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID PAPILLARY CARCINOMA; TRANSCRIPTION REGULATION; TUMOR GROWTH; UNDIFFERENTIATED CARCINOMA; CLASSIFICATION; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; INFORMATION PROCESSING; PATHOLOGY; PHYSIOLOGY; RNA PROCESSING; THYROID TUMOR;

BIOMARKERS, TUMOR; DATASETS AS TOPIC; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE SYSTEM; MICRORNAS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; THYROID NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84951131109     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141726     Document Type: Article

References (48)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. doi: 10. 3322/caac.21208 PMID: 24399786.
2. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, et al. Correlation between BRAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer. 2006; 13(2):455-64. doi: 10. 1677/erc.1.01086 PMID: 16728573.
3. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003; 22(41):6455-7. doi: 10.1038/sj.onc.1206739 PMID: 14508525.
4. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88(11):5399-404. PMID: 14602780.
5. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28(7):742-62. PMID: 17940185
6. Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer. 2006; 13 (1):257-69. PMID: 16601293
7. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63(7):1454-7. PMID: 12670889
8. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer. J Clin Oncol. 2014.
9. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005; 102(52):19075-80. PMID: 16365291
10. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 2006; 13(2):497-508. PMID: 16728577
11. Weber F, Teresi RE, Broelsch CE, Frilling A, Eng C. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab. 2006; 91(9):3584-91. PMID: 16822819
12. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene. 2007; 26(54):7590-5. PMID: 17563749
13. Tetzlaff MT, Liu A, Xu X, Master SR, Baldwin DA, Tobias JW, et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol. 2007; 18(3):163-73. PMID: 18058265
14. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008; 93(5):1600-8. doi: 10.1210/jc.2007-2696 PMID: 18270258
15. Kitano M, Rahbari R, Patterson EE, Xiong Y, Prasad NB, Wang Y, et al. Expression profiling of difficultto-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Ann Surg Oncol. 2011; 18(12):3443-52. doi: 10.1245/s10434-011-1766-4 PMID: 21553140
16. Chen YT, Kitabayashi N, Zhou XK, Fahey TJ, Scognamiglio T. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol. 2008; 21(9):1139-46. doi: 10.1038/modpathol. 2008.105 PMID: 18587330
17. Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A, Gundara JS, Ip JC, et al. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 2013; 119 (24):4358-65. doi: 10.1002/cncr.28254 PMID: 24301304
18. Rung J, Brazma A. Reuse of public genome-wide gene expression data. Nat Rev Genet. 2013; 14 (2):89-99. doi: 10.1038/nrg3394 PMID: 23269463
19. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167-214. doi: 10.1089/thy.2009.0110 PMID: 19860577
20. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform. 2011; 44(5):839-47. doi: 10.1016/j.jbi. 2011.05.002 PMID: 21605702
21. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2 (5):401-4. doi: 10.1158/2159-8290.CD-12-0095 PMID: 22588877
22. Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY, Lee JJ. Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem Biophys. 2013; 65(2):203-10. doi: 10. 1007/s12013-012-9419-1 PMID: 22907586
23. Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, Moon HS, Chamberland JP, Liu X, et al. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metab. 2011; 96(12):E2023-8. doi: 10.1210/jc.2010-1908 PMID: 21937620
24. Braun J, Hoang-Vu C, Dralle H, Hüttelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene. 2010; 29(29):4237-44. doi: 10.1038/onc. 2010.169 PMID: 20498632
25. Leone V, D'Angelo D, Rubio I, de Freitas PM, Federico A, Colamaio M, et al. MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. J Clin Endocrinol Metab. 2011; 96(9):E1388-98. doi: 10.1210/jc.2011-0345 PMID: 21752897
26. Guan H, Wei G, Wu J, Fang D, Liao Z, Xiao H, et al. Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer. J Clin Endocrinol Metab. 2013; 98(8):E1334-44. doi: 10.1210/jc.2013-1053 PMID: 23720784
27. Gao Y, Wang C, Shan Z, Guan H, Mao J, Fan C, et al. miRNA expression in a human papillary thyroid carcinoma cell line varies with invasiveness. Endocr J. 2010; 57(1):81-6. PMID: 19851034
28. Xiong Y, Zhang L, Holloway AK, Wu X, Su L, Kebebew E. MiR-886-3p regulates cell proliferation and migration, and is dysregulated in familial non-medullary thyroid cancer. PLoS One. 2011; 6(10): e24717. doi: 10.1371/journal.pone.0024717 PMID: 21998631
29. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007; 14(3):791-8. PMID: 17914108
30. Colamaio M, Borbone E, Russo L, Bianco M, Federico A, Califano D, et al. miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. J Clin Endocrinol Metab. 2011; 96(12): E1915-24. doi: 10.1210/jc.2011-0408 PMID: 21956418
31. Ward LS. Immune response in thyroid cancer: widening the boundaries. Scientifica (Cairo). 2014; 2014:125450.
32. Liotti F, Visciano C, Melillo RM. Inflammation in thyroid oncogenesis. Am J Cancer Res. 2012; 2 (3):286-97. PMID: 22679559
33. Fang W, Ye L, Shen L, Cai J, Huang F, Wei Q, et al. Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. Carcinogenesis. 2014; 35(8):1780-7. doi: 10.1093/carcin/bgu060 PMID: 24608042
34. Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, et al. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One. 2013; 8(1):e54302. doi: 10.1371/journal.pone.0054302 PMID: 23372702
35. Iwahashi N, Murakami H, Nimura Y, Takahashi M. Activation of RET tyrosine kinase regulates interleukin-8 production by multiple signaling pathways. Biochem Biophys Res Commun. 2002; 294(3):642-9. PMID: 12056817
36. Russell JP, Engiles JB, Rothstein JL. Proinflammatory mediators and genetic background in oncogene mediated tumor progression. J Immunol. 2004; 172(7):4059-67. PMID: 15034017.
37. Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, et al. Nuclear factor κB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab. 2014; 99(8):E1436-44. doi: 10.1210/jc.2013-3636 PMID: 24758177; PubMed Central PMCID: PMCPMC4121024.
38. Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria Florena A, et al. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res. 2006; 66(3):1491-9. PMID: 16452205
39. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res. 2003; 63(20):6784-90. PMID: 14583474
40. Vella V, Mineo R, Frasca F, Mazzon E, Pandini G, Vigneri R, et al. Interleukin-4 stimulates papillary thyroid cancer cell survival: implications in patients with thyroid cancer and concomitant Graves' disease. J Clin Endocrinol Metab. 2004; 89(6):2880-9. PMID: 15181072
41. Çil E, Kumral A, Kanmaz-Özer M, Vural P, Doʇru-Abbasoʇlu S, Altuntaş Y, et al. Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer. Mol Biol Rep. 2014; 41(5):3091-7. doi: 10.1007/s11033-014-3169-7 PMID: 24464184
42. Gao L, Zhu X, Li Z, Li L, Wang T, Hu H, et al. Association between a functional insertion/deletion polymorphism in IL1A gene and risk of papillary thyroid carcinoma. Tumour Biol. 2014; 35(4):3861-5. doi: 10.1007/s13277-013-1512-6 PMID: 24453029
43. Pacifico F, Crescenzi E, Mellone S, Iannetti A, Porrino N, Liguoro D, et al. Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a. J Clin Endocrinol Metab. 2010; 95(3):1421-30. doi: 10.1210/jc.2009-1128 PMID: 20061417
44. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, et al. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology. 2006; 147(12):5699-707. PMID: 16959844
45. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, et al. Association of IL10 and other immune response-and obesity-related genes with prostate cancer in CLUE II. Prostate. 2009; 69(8):874-85. doi: 10.1002/pros.20933 PMID: 19267370
46. Tsujikawa T, Yaguchi T, Ohmura G, Ohta S, Kobayashi A, Kawamura N, et al. Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma. Int J Cancer. 2013; 132(12):2755-66. doi: 10.1002/ijc.27966 PMID: 23180648
47. Hung JY, Horn D, Woodruff K, Prihoda T, LeSaux C, Peters J, et al. Colony-stimulating factor 1 potentiates lung cancer bone metastasis. Lab Invest. 2014; 94(4):371-81. doi: 10.1038/labinvest.2014.1 PMID: 24468794
48. Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012; 120(6):1290-8. doi: 10.1182/blood-2012-01-404699 PMID: 22723552